Kiran C. Patel, MD was until recently the Chairman and President of Freedom Health, Inc. Dr. Patel and also the Chairman and President of Optimum Healthcare, Inc. He is a Board-Certified cardiologist. Dr. Patel began his career in private practice. He quickly became recognized as a pre-eminent cardiologist and established a physician practice management company, which he grew to over 20 physicians and multiple locations. He is the founder of the Drs. Kiran and Pallavi Patel Family Foundation. Dr. Patel subsequently entered the managed care industry and was the Chairman of WellCare of Florida. While at WellCare, he acquired struggling HMOs in New York and Connecticut. Dr. Patel left WellCare in 2002. After that, Dr. Patel was under a non-compete agreement and thus became involved in healthcare informatics. He was a Member of Advisory Board of BelHealth Investment Partners, LLC. Among the honors and awards that he has received is the Ernst & Young Entrepreneur of the Year Award for the Southeast United States, Jefferson Award for Public Service-National Media Award, Community Leader Award-Community Development Corporation of Tampa, Lions Clubs International Academy Award for Humanitarian Service, and Ike Tribble Award from National Urban League. On New Year’s Day in 2007, Dr. Patel was honored with the “Glory of Gujarat” award from the Chief Minister of his home State in India. In May 2007, he received the Ellis Island Medal of Honor for Exceptional Immigrant Patriots. Dr. Patel completed his fellowship in Cardiology at Columbia University in 1982. He completed his residency in Internal Medicine in New Jersey after obtaining a Medical degree from Gujarat University in India and completed an internship in Africa. Dr. Patel studied under the British Educational System in Zambia and received a Diploma from Cambridge University in the United Kingdom. He also completed studies at the University of London.
Pat is a co-founder of Morphogenesis, Inc. and has served the Company as Chief Executive Officer since 2003. Pat also served as Morphogenesis’ Chief Operating Officer from 1996 until 2003. Pat previously served as Division Director of Cancer Molecular Biology at the Walt Disney Memorial Cancer Institute, where she initiated and led the multifaceted molecular biology, gene targeting, gene therapy, gene delivery, and universal stem cell projects. Pat holds degrees from the University of Florida in Anthropology, Plant Pathology, Immunology and Medical Microbiology with specialties in Hematology and Oncology and has held faculty positions at several Florida State Universities.
Michael is a co-founder of Morphogenesis, Inc. Michael received his PhD from the University of Surrey, UK, while working at the Animal Virus Research Institute (The Pirbright Institute). Michael came to the US as an NIH postdoctoral fellow at the University of Tennessee. Michael then served on the faculty of the Colleges of Veterinary Medicine at Auburn University and the University of Florida. Michael also worked as a senior scientist in the Division of Immunology and Cytokine Therapeutics of the Veterinary Infectious Disease Organization – Vaccine and Infectious Disease Organization (VIDO) of Canada. Michael also held a faculty position at the University of Florida in the College of Medicine and was Director of Research at the Walt Disney Memorial Cancer Institute. Michael has published extensively and is co-inventor on numerous US and world-wide patents. He has participated as a research consultant on a number of topics for the Biopharmaceutical Industry and for International and US agencies. Michael also served as a reviewer and as an Ad Hoc reviewer for a number of scientific journals.
David, a Fellow of The Securities Institute, has been associated with the London Stock Market since 1969. During that period, he has been actively involved in research and marketing of smaller companies at medium sized agency brokers such as Sheppards, Seymour Pierce and Williams de Broe. As a Director he has helped to establish successful corporate broking businesses which has involved him in both floating smaller companies on the London Aim market and raising equity finance for corporate clients. During his tenure he has established significant contacts with most of the small cap fund managers. David is currently a corporate broker with Daniel Stewart in London.
Grahame has 20 years’ experience in investment banking in the US and Europe. He was the Global CEO of West LB Panmure from 1999 and 2003, which he joined in 1999. Prior to that, from 1995, Grahame was Managing Director of Capital Markets and a member of the Global Investment Banking Management Committee at UBS. He has advised on many transactions in the pharmaceutical and biotechnology sectors. Grahame was a founder member of the LSE’s TechMARK Advisory Committee and holds an MA, double first, from Oxford University. Since 2003 he has mentored a number of healthcare companies. He was a seed investor in 2001 in Sinclair Pharma plc, which he has chaired for 9 years and is now a global dermatology company capitalized at $400m. He is on the Board of Horizon Discovery plc, an international genomics company which did an IPO raising $100m in 2014; MDY plc, a listed medtech investment company; and Actino Ltd, an immunotherapy company.
David Bergmann is the President and Founder of NAECO, LLC (established 1999) and other technology ventures. NAECO has been recognized twice in the INC® 5000 list of fastest growing US private businesses and four-times nominated as Georgia Manufacturer of the Year. A Biotech investor since 2011, David has a 27-year career in technical product development, prototyping, manufacturing and marketing. Through both organic growth and acquisitions, he led NAECO’s expansion into the Aerospace, Military and Medical markets, and holds 13 intellectual properties. As a supplier and collaborator, David has supported dozens of product development efforts for companies ranging from small startups to international corporations. His company holds globally recognized Quality certifications in Medical, Aerospace and Industrial manufacturing. David earned a MS degree in Industrial and Systems Engineering, and a BS in Applied Mathematics from the University of Florida. In addition to serving on Morphogenesis’ board, David serves on the Board of the Fayette County Chamber of Commerce. David has been married for nearly 23 years to his sweetheart, Tracy.
Mr. J. P. Errico is a Co-Founded electroCore LLC in 2005 and serves as its Chairman and Principal Investor. Mr. Errico has also been Chief Science & Strategy Officer of electroCore LLC since July 21, 2016. He served as the Chief Executive Officer of electroCore LLC until July 21, 2016. He founded Spinecore, Inc. and served as its Chief Executive Officer until July 2004. Mr. Errico has co-founded a number of medical device companies, including Fastenetix, K2 Medical, AD-4 Pharma, E2, and SpineCore. He serves as a Director of electroCore, LLC. Mr. Errico trained as a patent attorney in New York and is the author of a treatise on international intellectual property law. Mr. Errico is a named inventor on more than 125 issued US patents and is a named inventor on more than 100 pending US applications. Additional patents and patent applications outside the US on which he is a named inventor number greater than 200. Mr. Errico received his undergraduate degree in aeronautical engineering from the Massachusetts Institute of Technology and worked at the Air Force National Laboratory, Lincoln Laboratories. He holds both law and mechanical/materials engineering graduate degrees from Duke University.